Cell therapy of diabetes mellitus has been mainly based on islet transplantation. Transplantation of pancreatic islet cells as a potential cure for diabetes has become a subject of intense interest and activity over the past two decades [1] . Islet transplantation involves isolation of islets and their transplantation through a simple injection into the umbilical vein, an operation devoid of the many potential complications of transplantating the pancreas [2] . Several barriers still delay, however, the success of this approach such as: (1) the diabetogenic effects of some immunosupressant agents [3]; (2) immunological rejection [4]; (3) the oncogenic effects of long-term immunosuppressive treatment and (4) insufficient number of beta cells transplanted [5] . A recent report has established that insulin-independence could be reached by combining a glucocorticoid-free immunosuppression with the transplantation of an adequate islet mass [6] . This successful example will increase the demand for human islets. Even with the new immunosuppressive therapy and less traumatic islet isolation procedures, which could be devised in the future, the shortage of donors is such that it will not be possible to meet the demand from all the patients with Type I (insulin-dependent) diabetes mellitus, however, consequently protocols to obtain insulin-secreting cells from other sources need to be developed. In this sense, the strategic knowledge Diabetologia (2001) 
Cell therapy of diabetes mellitus has been mainly based on islet transplantation. Transplantation of pancreatic islet cells as a potential cure for diabetes has become a subject of intense interest and activity over the past two decades [1] . Islet transplantation involves isolation of islets and their transplantation through a simple injection into the umbilical vein, an operation devoid of the many potential complications of transplantating the pancreas [2] . Several barriers still delay, however, the success of this approach such as: (1) the diabetogenic effects of some immunosupressant agents [3] ; (2) immunological rejection [4] ; (3) the oncogenic effects of long-term immunosuppressive treatment and (4) insufficient number of beta cells transplanted [5] . A recent report has established that insulin-independence could be reached by combining a glucocorticoid-free immunosuppression with the transplantation of an adequate islet mass [6] . This successful example will increase the demand for human islets. Even with the new immunosuppressive therapy and less traumatic islet isolation procedures, which could be devised in the future, the shortage of donors is such that it will not be possible to meet the demand from all the patients with Type I (insulin-dependent) diabetes mellitus, however, consequently protocols to obtain insulin-secreting cells from other sources need to be developed. In this sense, the strategic knowledge Diabetologia (2001) achieved by molecular, cell and developmental biologists has supported the possibility of engineering islet cells to reconstruct pancreatic endocrine function [7] . A major goal for diabetes therapy is to genetically design an insulin-secreting artificial beta-cell. These beta-cells have potential advantages relative to islets isolated from cadaveric donors as a vehicle for insulin delivery: firstly, they can be grown at low cost and in essentially unlimited numbers under pathogen free conditions and secondly, because they are clonal by nature, those clones which retain functional features which are highly reproducible can be selected at will [8, 9] . Most of the efforts have concentrated so far on the availability of beta-cell surrogates using tumour or transformed cell lines which can be modified to express the defective gene [7, 10, 11] . Use of tumoural cell lines, either of pancreatic or neuroendocrine origin in cell therapy of diabetes is restricted by several limitations [12±22]: firstly, tumoural cell lines retain their neoplastic nature; secondly, as a consequence of phenotypic instability and inadequate gene expression most beta-cell lines show maximum glucose responsiveness at considerably decreased glucose concentrations than those observed in normal islets and they tend to lose insulin biosynthesis and regulated secretion with the successive number of passages; and thirdly, cell lines present primitive differentiation features or even remnants of the parental cells. Proliferating islet cells of human origin have also been genetically modified to produce insulin-secreting cell lines [23±26] . In this regard, transfection of subconfluent monolayers of neonatal islet cells from patients suffering from persistent hyperinsulinaemic hypoglycaemia in infancy with the corresponding defective genes [sulphonylurea receptor (SUR-1), Kir6.2, homeodomain transcription factor pancreas/duodenum homeobox-1 (PDX-1)] results in a clonal cell line which shows glucose-sensitive insulin secretion within the normal range [27] .
Stem cells, either pluripotent or committed to be beta cells, represent a potentially unlimited source of beta cells. Beta cells, in theory, could be derived from pluripotent stem cells [embryonic stem cells (ESC); embryonic germ cells (EGC) or teratocarcinoma, embryonal carcinoma cells (ECC)] or from their direct progenitor, the pancreatic ductal cells (Fig. 1) . Recently the mechanisms that control pancreatic development have been explained in part. In the early stages signals are derived from the notochord [fibroblast growth factor (FGF) 2, activin bB], and in later stages from mesenchymal which then induce proliferation and differentiation of pancreatic epithelial cells into islet cells [28] . The list of transcriptional factors implicated in pancreatic development identified so far include: Pdx-1, Pax-4 and Pax-6, islet-1, beta2, NeuroD, Nkx2.2, Nkx6.1, Hexb9, neurogenin and p48. Knock-out mice lacking such factors show altered patterns in their pancreatic development. The capability to control islet cell differentiation, regeneration, growth and neogenesis has been discussed [7] . Major obstacles in the use of stem cells to reconstruct pancreatic function are: firstly, the need to design procedures to obtain, select and stimulate maturation of insulin-containing cells; secondly, the prevention of immunorejection, and thirdly, potential bioethical concerns. Designed cell lines could, however, have many advantages including unlimited cell supply; functional consistency; engineered immunoprotection that can avoid the onco- Endoderm-derived cells (gut, liver, exocrine and endocrine pancreas) have been very difficult to obtain. The sequence of events, growth factors, cell-tocell interactions, extracellular matrix factors and signalling pathways involved in the endoderm lineage pathway are beginning to be deciphered using a variety of molecular and developmental genetic approaches. Thus, there is still little knowledge on how to induce ESC into a particular endoderm path and the architectural complexity of epithelial tissue points to the importance of cell-to-cell interactions [43, 44] . One solution is to partially reproduce the environmental conditions by coculturing pluripotent stem cells with the pancreatic primordial tissue which appears early in the mouse embryo development (E8.5-E9) or with adjacent germ layers, thus providing the soluble factors that induce early endoderm differentiation [45] .
Embryoid bodies (EB) reproduce some of the conditions given for cell differentiation: they are polarised; there are cell-to-cell interactions; there exist asymmetric contacts and growth factors are being produced. Concerning pancreatic cells at day 12, embryoid bodies (EB) from a strain, 129 embryonicstem cell line (ENS ES) express transcripts of endocrine (i. e., insulin, glucagon and PP) and exocrine (i. e., amylase, elastase and carboxypeptidase) specific genes, suggesting that transcriptional factors involved in their regulation are functional in these embryonic stem cells (Fig. 2) . Finally, D3 embryonic stem cells when maintained in an undifferentiated state (in the presence of leukaemia inhibitory factor) were positive for insulin (3 out of 52 cells, Fig. 3A ) and glucagon (3 out of 50 cells, Fig. 3B ).
Cell selection methods. Even in improved conditions used to induce ESC differentiation, this process results in a mixture of cell types. The percentage of differentiated cells belonging to one phenotype remains very small (i. e. 0.1 to 0.5 %). Therefore, this mixed population is not suitable for transplantation or cell therapy and additional strategies are required to obtain pure populations of cells with the desired phenotypes. Selection of specific cell types could be based on the expressed phenotype (i. e. a membrane report- . We have adapted this methodology for the selection of insulin-containing cells [8] . Our cell-trapping system consists of transfecting the embryonic stem (ES) cells with a chimeric construct, which functionally couples the regulatory region of the human insulin gene to a gene that confers resistance to a drug (i. e. the neomycin resistance gene) (Fig. 4) . Thus, those cells, which express the protein of interest, will also express the drug resistance gene. By a similar strategy murine cardiomyocytes have been obtained that form stable intracardiac grafts when transplanted into adult dystrophic mice [46] , also bringing about the production of neural precursors [47] or forcing the expression of a transcription factor such as Oct3/4, thereby keeping embryonic stem cells in an undifferentiated state [48] . Another approximation for the genetic selection method is the transfection of ESC by gene encoding, the green fluorescent protein under the control of the cardiac a-actin promoter [49] . Upon differentiation only cardiomyocytes expressed the green fluorescent protein, it being possible to isolate them by cell sorting.
Cell maturation. Altogether these data indicate that specific and relative pure cell types can be isolated from in vitro differentiated ESC. In some cases, however, these differentiated cells need to undergo a final maturation process to be completely functional. This was the case with the islet progenitor cell-derived islets [9] or the embryonic stem-derived insulin-secreting cells [8] . In both situations, the cells had a low insulin content and an inefficient release of insulin. Thus, it is very important to understand the factors, which provide a permissive in vitro environment allowing islet neogenesis from duct cells, acinar cells or stem cells to further mature and/or differentiate into fully functional islets with maximum insulin production capacity. Among them are vascular endothelial growth factor [50], hepatocyte growth factor [51], transforming growth factor [52] , islet neogenesis-associated protein [53] , regenerating gene-1 [54] , insulin-like growth factor [55] , gastrin [56] , epidermal growth factor [57] and activin A and betacellulin [58] .
The majority of the maturation protocols are based on studies from fetal islets [59] , rat pancreatic regeneration [60] and adult pancreatic duct cells [61] . Some of these protocols used nicotinamide as a differentiation factor [62, 63] . These studies, together with the fact that glucose is a major modulator of gene expression in beta-cells and that sustained hyperglycaemia can produce considerable phenotypic changes which altered the pattern of beta-cell differentiation and insulin secretion [15, 64±66], led us to follow a maturation strategy mainly based on the use of nicotinamide and non-stimulatory glucose concentrations (Fig. 5 ) [8] . Over 2 weeks culture in 10 mmol/l nicotinamide and another week in 10 mmol/l nicotinamide plus 5 mmol/l glucose the insulin content of the cells increased 20-fold and the cells showed a good secretagogue-induced insulin response to different secretagogues [8] . Recently, it has been shown that human ductal tissue could be expanded in culture and then directed to differentiate in vitro [61] . The step-by-step maturation protocol consist of the following: (1) adherent cells after 1 to 4 days of culture are expanded for up to 1 week until they form monolayers, (2) the media is changed to serum-free DMEM with 8 mmol/l glucose, ITS supplement (insulin + transferrin + selenium), 10 mmol/l nicotinamide and keratonicyte growth factor for 1 to 2 more weeks, (3) cells are layered with Matrigel, a commercial preparation of murine basement membrane. This procedure yields a high proportion of insulin positive cells which respond to glucose.
Stem-derived cell replacement therapies
At present, the most urgent problem in transplantation is the lack of suitable donors. One alternative to organ transplantation is ESC-based cell therapy. This strategy is based on the idea that pluripotent stem cells can be used to produce large numbers of cells that can be genetically modified in vitro to differentiate along a given pathway, thus obviating the need for fetal tissues. Obviously, the clinical targets of cell therapy are neurodegenerative disorders (Alzheimer and Parkinson's diseases), diabetes, spinal cord injuries, cardiovascular diseases, osteoporosis, autoimmune diseases, cancer, severe burns, muscular dystrophies, haematopoietic repopulation and birth defects. At the experimental stage, this concept needs to be proved by using animal models of disease to which cell therapy can be applied to show its therapeutic benefit. Until now, only three groups of investigators have gone this far in using ESC. One group has used differentiation and cell selection protocols to generate D3 ESC-derived cardiomyocytes that formed stable intracardiac grafts for as long as 7 weeks after implantation [46, 47] . Another group showed that immature nerve cells generated from mouse embryonic stem cells and transplanted into damaged spinal cords of rats partially restored the animals' spinal cord function [68] . In addition, using a similar approach we have produced an insulin-secreting cell derived from R1 mouse embryonic stem cells that restores blood glucose concentrations to normal when transplanted into streptozotocin-induced diabetic animals. The animals transplanted with the final clone IB/3x-99 corrected the hyperglycaemia within 1 week (Fig. 6A) , restored body weight in 4 weeks (Fig. 6B ) and showed normal blood glucose concentrations after a challenge meal similar to that of control mice (n = 10) [8] . Notably, 3 mice were normoglycaemic for more than 12 months (data not shown). In addition, a recent report showed that functional islets derived from ductal structures of non-obese diabetic (NOD) mice could reverse insulin-dependent diabetes when transplanted into diabetic non-obese mice [9] . Before the transplantation of embryonic stem-derived cells to humans can be accomplished, several theoretical and experimental problems must be overcome. Firstly, equilibrium has to be attained between the proliferative capacity, lack of tumourigenicity, and differentiation potential. Ideally, the molecular basis of such a delicate equilibrium should be unravelled so that it can be used in a variety of situations. In our study, the construction engineered and the maturation strategy followed rendered clones which were not tumourigenics but whose proliferative potential was still suboptimal: approximately 40 % of the animals receiving transplants developed hyperglycaemia 12 weeks after transplantation probably because of the limited lifespan of the implanted cell cluster [8] . Secondly, any cells used in transplantation would need to be autologous or immunologymasked. The immunological destruction of the graft could be at the origin of the reversal of normoglycaemia observed in some of our mice implanted with ESC. Thirdly, it is important to identify the appropriate site integration of selection vectors to achieve high expressions of the transgenes thus allowing us to select a pure population of cells. In our case, the transgenes were appropriately expressed even 4 months after the engraftment in diabetic animals, as shown by the X-Gal staining in IB/3x-99 cells (n = 3, Fig. 7A ). Pure populations of cell types is a prerequisite because introduction of contaminating pluripotent ESC during transplantation might give rise to teratomas [8] . Finally, cells need to have homogeneous and stable phenotypes. Immunohistochemistry studies of the spleen of normoglycaemic animals showed insulin-expressing IB/3x-99 cells 4 months after engraftments (n = 3, Fig. 7B ).
The studies using ESC [46, 68, 8] show that specific and relatively pure cell types can be isolated from differentiated ESC in vitro and successfully transplanted. Although it is not clear if human ESC can be genetically modified and specific cell types isolated, the development of human embryonic stem C lines [41, 42] should facilitate their use for cell therapy to become a reality.
Future perspectives in stem cell research
Apart from reproductive cloning, the creation of Dolly the cloned sheep [69] has opened two main possibilities. Theoretically, nuclear transfer from a patient's cell to a recipient enucleated cell (either oocyte, embryonic stem or EG cells) would make it possible to obtain ªcustomisedº embryonic stem cells that could be induced to differentiate into human tissues and cell lineages useful for cell therapy of diseases like diabetes mellitus. Conceptually, given that nuclear DNA in adult somatic tissues can be reprogrammed to regain its pluripotentiality [70] , it should be possible in principle to obtain pluripotential stem cells from adult tissues. This hitherto unrecognised plasticity could be exploited to generate cells and tissues for autologous grafts. Whereas these notions are not likely, the newly discovered versatility of some somatic stem cells invites us to test this possibility for stem cell therapeutics. In the new method, cells or nuclei will only be temporally committed and their localisation in a totipotent environment would induce these cells to abandon the previous stage and acquire a new developmental phenotype. In therapeutic terms, it might be irrelevant whether these cells are resident totipotent stem cells or whether they differentiate into a totipotent stage, provided that they are used to generate cells and tissues for transplantation. Clearly, the exploitation of both genetic and epigenetic factors will be at the basis of such developments.
Recently, several reports have appeared that add new insights and perspectives to the prevailing concepts of somatic stem cell potentials. There are suggestions that the functional plasticity of somatic tissue-derived stem cells might be greater than expect- ed. Adult stem cells from mouse brain can pass to the blood stream and bone marrow and become mature blood cells [71] . Similarly, stem-cell populations originally obtained from muscle show a robust transplantable haematopoietic activity [72] . More recently, it has been shown that a human adult haematopoietic stem-cell population is capable of yielding an epithelial lineage (adult human liver cells) [73] . Once it is accepted that cells from adult subjects can be reprogrammed to express a distinct phenotype, the existence of putative pluripotential stem cells in adult tissues will be the next step to establish. Our group has observed that cells isolated from adult intestine, when appropriately cultured, expressed markers from each of the three embryonic germ layers (data not shown). Apart from circumventing the ethical dilemmas surrounding research on embryonic and fetal stem cells, adult stem cells possess another advantage which is that they could be obtained from the patient, thus allowing autotransplantation. Theoretical drawbacks, however, such as a shorter lifespan (making them less suitable for medical applications), which might limit their use, have to be addressed.
In conclusion, we are still far from understanding the processes involved in stem cell self-renewal and differentiation, yet the potential uses for stem cells seem endless. Nevertheless, we are aware that a major difference exists between autoimmune diabetes, which is treatable with insulin, and life-threatening diseases like kidney or heart failure. Before cell therapy can be applied the risks and benefits have to be properly balanced. For example, long-term threatment with immunosuppresive agents in patients with long life expectancy could result in an increased rate of malignancies. In recent years, stem cell biology has been advancing at an incredibly rapid pace and evidence is accumulating that shows the enormous potential of stem cell technology, which might hold the answer to cure some devastating diseases such as diabetes. 
